Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Arabidopsis thaliana XXT2-XXT5 Heterodimer

ABSTRACT: Two purified proteins, Xyloglucan Xylosyltransferases 2 and 5 (Uniprot accession numbers uniprot accession number) suspected of forming a complex were analyzed and quantified to confirm complex formation.

INSTRUMENT(S):

ORGANISM(S): Arabidopsis Thaliana (mouse-ear Cress)

SUBMITTER: Jordan Julian

LAB HEAD: Olga A

PROVIDER: PXD067849 | Pride | 2026-05-05

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	P1302-01_10-06.msf	Msf
	P1302-01_10-06.raw	Raw
	P1302-02_9-15.msf	Msf
	P1302-02_9-15.raw	Raw
	P1307-02_10-27.msf	Msf

Items per page:

1 - 5 of 6

Similar Datasets

Supercharging-Enhanced nDIA-MS Enables Global Profiling of Drug-Induced Proteome Solubility Shifts (co-solvent)

Project description:Mass spectrometry (MS)-based proteomics has become indispensable for high-throughput quantitation of protein expression. However, protein function is regulated by a vari-ety of factors beyond abundance alone. Here, we optimized narrow-window, data-independent acquisition (nDIA) MS with 3% DMSO as a supercharging co-solvent, boosting signal intensity by up to 56% and enabling identification of ~9,600 proteins from 1 µg of HeLa digest with a 15 min gradient. Using this methodology, we quantified solubility and abundance changes in 8,694 proteins across three cell lines following short-term treatment with the proteasome in-hibitor MG132 and the SUMO-activating enzyme inhibitor ML-792. MG132 affected the solubil-ity of 1,723 proteins and the abundance of 374, and ML-792 impacted 1,294 and 288, respec-tively. The drugs elicited distinct and sometimes opposing solubility shifts; For instance, MG132 insolubilized HSF1, ML-792 solubilized SP100 and insolubilized PLOR3G, and SMAD2 showed opposite responses to those two treatments. These results reveal wide-spread, drug-induced remodeling of the protein solubility landscape and establish solubility profiling by nDIA-MS as a robust and broadly applicable platform for uncovering protein state transitions and cellular responses to perturbation.

2026-01-11 | PXD064180 | Pride

Supercharging-Enhanced nDIA-MS Enables Global Profiling of Drug-Induced Proteome Solubility Shifts (solubility proteomics)

Project description:Mass spectrometry (MS)-based proteomics has become indispensable for high-throughput quantitation of protein expression. However, protein function is regulated by a variety of factors beyond abundance alone. Here, we optimized narrow-window, data-independent ac-quisition (nDIA) MS with 3% DMSO as a supercharging co-solvent, boosting signal intensity by up to 56% and enabling identification of ~9,600 proteins from 1 µg of HeLa digest with a 15 min gradient. Using this methodology, we quantified solubility and abundance changes in 8,694 pro-teins across three cell lines following short-term treatment with the proteasome inhibitor MG132 and the SUMO-activating enzyme inhibitor ML-792. MG132 affected the solubility of 1,723 pro-teins and the abundance of 374, and ML-792 impacted 1,294 and 288, respectively. The drugs elicited distinct and sometimes opposing solubility shifts; For instance, MG132 insolubilized HSF1, ML-792 solubilized SP100 and insolubilized PLOR3G, and SMAD2 showed opposite responses to those two treatments. These results reveal widespread, drug-induced remodeling of the pro-tein solubility landscape and establish solubility profiling by nDIA-MS as a robust and broadly ap-plicable platform for uncovering protein state transitions and cellular responses to perturbation.

2026-01-12 | PXD064185 | Pride

Induction of anti-tumour immunogenicity via modulation of nonsense-mediated decay

Project description:This project explores the role of SMG1 on the Nonsense-mediated decay (NMD) pathway in two human cell lines – PC9 (lung) and A375 (epithelial). The conditions used were a DMSO control for two SMG1 inhibitors, and an siRNA control for the siSMG1 RNA knock-down condition.

2026-04-07 | PXD063528 | Pride

Recombinant Ag85B Glycoproteomics

Project description:A bacterial antigen (Ag85B) was recombinantly expressed in Expi293 cells in which non-native N-glycosylation occured. We used glycoproteomics to characterize site-specific glycosylation across the surface of Ag85B as informed by glycomics data.

2026-05-25 | PXD077483 | Pride

Phosphoproteomic study looking at the effect of a novel PI3Kα modulator on PI3Kα-WT and PI3Kα-KO mouse embryonic fibroblastsPhosphoproteomic study looking at the effect of a novel PI3Kα modulator on PI3Kα-WT and PI3Kα-KO mouse embryonic fibroblastsPhosphoproteomic study looking at the effect of a novel PI3Kα modulator on PI3Kα-WT and PI3Kα-KO mouse embryonic fibroblasts

Project description:This project looks at the effect a chemical modulator targeting PI3Kα has on the phosphoproteome of PI3Kα-WT and PI3Kα-KO MEFs. PI3K signalling is a critical regulator of numerous cellular processes such as proliferation, apoptosis, migration, invasion, metabolism, cell growth and autophagy. The PI3K pathway is frequently hyperactivated in cancer, commonly due to activating mutations or via loss of the lipid phosphatases that negatively regulate the pathway. We have recently identified a new small molecule modulator of the PI3K pathway and have used an unbiased phosphoproteomics approach to examine the impact of this compound on signalling pathways in cells that are wild-type and knockout for PI3K. Immortalised mouse embryonic fibroblasts (MEFs) isolated from PI3Kα-WT and PI3Kα-KO embryos were treated with and without the modulator (5 µM), exploring early (15 min) and late (4 h) time points. Insulin is a well-characterised activator of PI3K. Therefore, PI3Kα-WT MEFs were also treated with insulin (100 nM) as a positive control to compare with the PI3K modulator.

2023-03-06 | PXD027993 | Pride

glc and 1-NM-PP1 timecourses in tpk1/2/3as; TMT2 (4646)

Project description:Samples taken at different timepoints after glucose addition. Strain ACY142. Different timepoints after 1-NM-PP1; for model building

2024-06-16 | PXD036029 | Pride

Kinase pathways in cilia disassembly signalling

Project description:Aim: To determine the major protein kinase pathways altered upon serum- or LPA-induced cilia disassembly Primary cilia are dynamic structures which must disassemble for a cell to go through mitosis and re-assemble in G0 to transduce essential signals. Also, in non-cycling cells (such as renal epithelial cells), there is evidence to suggest that deregulated cilia disassembly is of critical importance, for example in instances with an excess of a cilia disassembly stimuli (such as Aurora kinase A expression and activation, a key disassembly factor) which is associated with ciliopathy phenotypes and a net loss of ciliated cells. Serum, growth factor or lysophosphatidic acid (LPA) stimulation of ciliated cells are well established experimental paradigms for the induction of cilia disassembly. The signalling network activated by these stimuli that culminates in cilia disassembly is complex and poorly understood. Studies have generally focused on a single or small group of proteins of interest to define their roles in cilia disassembly and the key pathways and kinases activated upon serum stimulation to induce cilia disassembly have not been defined. Moreover, to the best of our knowledge an unbiased analysis of the major pathways activated during cilia disassembly has not been performed. Ciliated hTERT-RPE1 cells were treated with 10% serum or 2 M LPA for 15’ or 2 h to initiate cilia disassembly + pan-class I PI3K inhibitor GDC-0941, followed by label-free phosphoproteomics.

2024-07-25 | PXD046462 | Pride

Global proteomic effects of rapidly reversible electrophiles

Project description:Study the total protein levels following treatment with rapidly reversible small molecules

2024-06-08 | PXD050274 | Pride

Platelet derived S100A9 contributes to Endotheliopathy in Alcohol-Associated Hepatitis

Project description:Alcohol-associated liver disease (ALD) is a growing global health concern, with alcohol-associated hepatitis (AH) leading to the highest morbidity and mortality. Available therapies are limited and often inadequate. Platelets contribute in a variety of ways to the pathogenesis of liver diseases, but their role in AH remains largely unexplored. In this study we address the hypothesis that platelets contribute to pathological inflammation in AH. Using patient samples and a multi-omics approach, we found that platelets undergo proinflammatory transcriptomic and proteomic changes in AH, with two alarmins, S100A8 and S100A9, being among the top upregulated genes/proteins. Additionally, the abundance of platelet-derived microparticles containing S100A8 and S100A9 in AH patient plasma was increased (p=0.032) and correlated with disease severity (MELD-Na, r=0.51, p=0.03) and endotheliopathy (ICAM1, r=0.70, p=0.001) (CXCL8, r=0.48, p=0.04) (vWF, r=0.59, p=0.01). We mechanistically linked S100A9 with endotheliopathy via crosstalk between primary human liver sinusoidal endothelial cells and primary human monocytes. We also demonstrate that Interleukin-6 (IL6) upregulates S100A9 in megakaryocytic cells in a JAK/STAT-dependent manner, modeling changes occurring in the bone marrow in patients with AH. Our studies establish proinflammatory platelets as important contributors to AH disease pathology. Moreover, anti-platelet agents, or more specifically S100A9 targeted drugs, are potential therapeutic strategies in AH.

2026-06-26 | PXD078511 | Pride

Dimethyl Sulfoxide Enhances HLA Peptide Identification

Project description:Immunopeptidomics relies on LC-MS/MS for comprehensive profiling of HLA-bound peptides, yet detection remains challenging due to their non-tryptic nature, variable lengths, and lack of basic residues, which limit ionisation and fragmentation efficiency. To address these limitations, we investigated the impact of incorporating 5% dimethyl sulfoxide (DMSO) into LC-MS/MS mobile phase buffers on immunopeptidomic workflows. Using B-lymphoblastoid cell lines expressing HLA class I and II alleles and elastase-digested HeLa lysates as a surrogate for non-tryptic peptides, we assessed peptide identification, ionisation efficiency, charge state distribution, and fragmentation quality. DMSO significantly increased peptide identifications across all sample types, with gains of ~1.33-fold for HLA class I, ~1.55-fold for HLA class II, and ~1.24-fold for elastase digests. Improvements were systematic and reproducible, driven by enhanced electrospray ionisation, higher charge states, and superior MS2 spectral quality, evidenced by a two-fold increase in b- and y-ion intensities. Importantly, DMSO did not introduce major sequence bias, preserving motif integrity and predicted binding characteristics. Overall, these findings establish DMSO as a robust additive for improving sensitivity and reliability in immunopeptidomics, particularly for low-input or clinically derived samples.

2026-03-30 | PXD072997 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data